The short-term studies of major depressive disorder and other psychiatric disorders showed that in comparison with placebo antidepressants increased the risk of suicidality in children, adolescents and young people. If you want to use imipramine hydrochloride or any other antidepressant for a child, adolescent, or young adult you must think about this risk and compare it with the medical demand. Depression states and other psychiatric deviations are tied with the risk of suicide. Patients irrespective of age being cured with antidepressant therapy should be appropriately supervised and observed concerning the clinical worsening of their state, suicidal thinking or unusual changes in behavior. The doctors should consult the family members and caregivers about the necessity of an attentive observation and close contact with the prescribed patients. Remember that imipramine hydrochloride is not approved for children treatment.